Back to Search
Start Over
Evaluation of pre-diagnostic blood protein measurements for predicting survival after lung cancer diagnosis.
- Source :
-
EBioMedicine [EBioMedicine] 2023 Jun; Vol. 92, pp. 104623. Date of Electronic Publication: 2023 May 24. - Publication Year :
- 2023
-
Abstract
- Background: To evaluate whether circulating proteins are associated with survival after lung cancer diagnosis, and whether they can improve prediction of prognosis.<br />Methods: We measured up to 1159 proteins in blood samples from 708 participants in 6 cohorts. Samples were collected within 3 years prior to lung cancer diagnosis. We used Cox proportional hazards models to identify proteins associated with overall mortality after lung cancer diagnosis. To evaluate model performance, we used a round-robin approach in which models were fit in 5 cohorts and evaluated in the 6th cohort. Specifically, we fit a model including 5 proteins and clinical parameters and compared its performance with clinical parameters only.<br />Findings: There were 86 proteins nominally associated with mortality (p < 0.05), but only CDCP1 remained statistically significant after accounting for multiple testing (hazard ratio per standard deviation: 1.19, 95% CI: 1.10-1.30, unadjusted p = 0.00004). The external C-index for the protein-based model was 0.63 (95% CI: 0.61-0.66), compared with 0.62 (95% CI: 0.59-0.64) for the model with clinical parameters only. Inclusion of proteins did not provide a statistically significant improvement in discrimination (C-index difference: 0.015, 95% CI: -0.003 to 0.035).<br />Interpretation: Blood proteins measured within 3 years prior to lung cancer diagnosis were not strongly associated with lung cancer survival, nor did they importantly improve prediction of prognosis beyond clinical information.<br />Funding: No explicit funding for this study. Authors and data collection supported by the US National Cancer Institute (U19CA203654), INCA (France, 2019-1-TABAC-01), Cancer Research Foundation of Northern Sweden (AMP19-962), and Swedish Department of Health Ministry.<br />Competing Interests: Declaration of interests Jian-Min Yuan has a declaration on NIH grant funding, and the other authors have no conflicts of interest.<br /> (Copyright © 2023 World Health Organization. Published by Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2352-3964
- Volume :
- 92
- Database :
- MEDLINE
- Journal :
- EBioMedicine
- Publication Type :
- Academic Journal
- Accession number :
- 37236058
- Full Text :
- https://doi.org/10.1016/j.ebiom.2023.104623